STOCK TITAN
  1. Home
  2. News
  3. AYTU

Aytu BioPharma Inc - AYTU STOCK NEWS

Welcome to our dedicated news page for Aytu BioPharma (Ticker: AYTU), a resource for investors and traders seeking the latest updates and insights on Aytu BioPharma.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Aytu BioPharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Aytu BioPharma's position in the market.

News
Aytu BioPharma Reports Record Revenues, Record Prescriptions, and Highest Adjusted EBITDA in Company History for the Fourth Quarter of Fiscal Year 2023
Rhea-AI Summary
Aytu BioPharma reports Q4 2023 net revenue of $30.7 million, a 12% increase YoY, and adjusted EBITDA of $7.7 million. Q4 2023 total prescriptions increased 32% YoY. Rx segment net revenue was $23.3 million with adjusted EBITDA of $8.3 million. Consumer Health revenue decreased 15% YoY. Gross margins improved to 60% in Q4 2023. Net loss was $2.5 million in Q4 2023. Cash and cash equivalents were $23.0 million at June 30, 2023. FY 2023 net revenue was $107.4 million, an 11% increase YoY. Rx segment net revenue was $73.8 million. ADHD products net revenue increased 9% YoY. Pediatric products net revenue increased 58% YoY. Consumer Health revenue decreased 5% YoY. Gross margins improved to 62% in FY 2023. Net loss was $17.1 million in FY 2023. Total adjusted EBITDA was positive $3.2 million in FY 2023. Aytu plans to de-emphasize and monetize the Consumer Health segment. Management expects continued growth in the Rx segment and aims for consistent profitability and positive cash flow.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.48%
Tags
earnings
-
News
Aytu BioPharma to Report Fourth Quarter and Fiscal 2023 Financial Results on September 27, 2023
Rhea-AI Summary
Aytu BioPharma to report Q4 and fiscal year 2023 financial results on September 27, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.64%
Tags
conferences earnings
-
News
Aytu BioPharma to Present at LD Micro Main Event XVI Conference
Rhea-AI Summary
Aytu BioPharma to participate in LD Micro Main Event XVI Conference on October 3-5, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.7%
Tags
conferences
News
Aytu BioPharma Announces Exclusive Agreement with Medomie Pharma Ltd. to Commercialize Adzenys XR-ODT(R) and Cotempla XR-ODT(R) in Israel and the Palestinian Authority
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.62%
Tags
none
-
News
Aytu BioPharma Announces Submission of Cotempla XR-ODT(R) Manufacturing Site Transfer Prior Approval Supplement
Rhea-AI Summary
Aytu BioPharma has submitted a Prior Approval Supplement (PAS) to the FDA for the transfer of Cotempla XR-ODT production to a third-party manufacturer. The company expects a six-month review and potential FDA approval by late 2023 or early 2024. The transfer of Adzenys XR-ODT production has already begun, with margin improvements expected in early 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.36%
Tags
none
-
News
Aytu to Participate in the Maxim Group Virtual Healthcare Conference
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.69%
Tags
conferences
News
Aytu BioPharma Announces Closing of $4.0 Million Public Offering Priced At-the-Market
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.59%
Tags
offering
-
News
Aytu BioPharma Announces Pricing of $4.0 Million Public Offering Priced At-The-Market and the Appointment of a New Director
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.91%
Tags
offering management
-
News
Aytu BioPharma Reports Third Quarter of Fiscal Year 2023 Financial Results
Rhea-AI Summary
Aytu BioPharma announces Q3 2023 financial and operational results, with total prescriptions reaching a record high of 153,452, a 32% increase compared to Q3 2022. Net revenue was $22.7 million, a decrease of 6% from the year-ago quarter. Gross margins improved to 56% in Q3 2023. Net loss was $(7.2) million, compared to $(53.3) million in Q3 2022.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.21%
Tags
earnings
News
Aytu BioPharma to Report Third Quarter Fiscal 2023 Financial Results on May 11, 2023
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.16%
Tags
conferences earnings
Stock AYTU logo
Aytu BioPharma Inc

Nasdaq:AYTU

AYTU Rankings

#5223 Ranked by Market Cap
#3164 Ranked by Stock Gains
N/A Ranked by Dividends

AYTU Stock Data

15.92M
3.80M
3.49%
31.78%
6.48%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Loveland

About AYTU

aytu bioscience is a specialty healthcare company focused on developing and commercializing novel products in the field of urology. aytu is initially concentrating on prostate cancer, male premature ejaculation and male infertility and plans to expand into other urological indications for which there are significant medical needs. the company currently markets prostascint®, an fda-approved radioimaging agent indicated to detect prostate specific membrane antigen (psma) in the assessment and staging of prostate cancer. the company’s most advanced therapeutic is zertane™, an oral therapeutic entering phase 3 clinical studies in the united states as an as needed treatment for premature ejaculation (pe). aytu is also conducting clinical trials with the company’s mioxsys™ system as a novel, point-of-care diagnostic system with the potential to become a standard of care in the diagnosis and management of male infertility.